HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.

3rd Edition of Global Conference on

Addiction Medicine, Behavioral Health and Psychiatry

October 24-26, 2022 | Orlando, Florida, USA

GAB 2021

Zolmitriptan, a 5 HT1B receptor agonist, attenuates the rewarding effects of methamphetamine in adolescent rats

Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2021 - Brendan Coyne
California State University, , United States
Title : Zolmitriptan, a 5 HT1B receptor agonist, attenuates the rewarding effects of methamphetamine in adolescent rats


Activation of 5-HT1B receptors was previously found to disrupt the expression, but not the acquisition of methamphetamine (METH) conditioned place preference in adult mice, an animal model of drug reward. The present study tested the hypothesis that activation of 5-HT1B receptors would attenuate the acquisition of METH reward in adolescent male and female rats. Specifically, we examined whether Zolmitriptan, a 5-HT1B/1D agonist, modulates the acquisition of METHinduced CPP. Beginning on postnatal day (PD) 28, male and female adolescent rats underwent a 10-day methamphetamine CPP procedure. On days 1 and 10, rats were tested for their pre-conditioning and post-conditioning place preferences, respectively, during 20-min sessions. On days 2 -9, rats underwent 30-min conditioning sessions with saline in their initially preferred chamber or METH (0, 0.125, 0.25, 0.5, 1.0 mg/kg) in their initially non-preferred chamber on alternating days. For male rats, administration of Zolmitriptan (10mg/kg) 15 min before METH dose-dependently decreased preference for the METH-paired environment. Female rats displayed METH CPP after administering any dose of METH (i.e., 0.125-1.0 mg/kg). However, pretreatment with Zolmitriptan modestly reduced the preference for the METH-paired compartment. These results indicate that Zolmitriptan reduces METH reward in male and female adolescent rats. Furthermore, our findings, coupled with previous research, suggest that age, sex, and species may be important determinants for 5-HT1B-mediated attenuation of METH reward. Overall, these findings add to a growing body of literature that implicates 5-HT1B receptors as a potential target for psychostimulant addiction treatments.


Brendan Coyne is an undergraduate neuroscience researcher who studied Molecular Cell Biology and Chemistry at California State University Long Beach. He will be graduating with a BS in May 2021, subsequently matriculating into either Loyola’s Master of Science in Medical Physiology program or George Washington’s School of Medicine and Health Sciences. He has conducted behavioral addiction research in Dr. Zavala’s lab for approximately three years, presenting his work at numerous conferences and symposiums. He is currently authoring his Honors thesis as well as two manuscripts that will be submitted for publication.